April 5, AACR Annual Meeting (AACR 2024) opened at the San Diego Convention Center, San Diego, California. SynRx Therapeutics attended the meeting and presented the latest preclinical data from the project in the form of posters.

Wall poster information:

7119 / 20 - Clinic-ready Polθ inhibitor SYX1097 suppresses solid tumors in vivo

April 7, 2024, 1:30 PM - 5:00 PM  

Section 17

We have developed SYX1097, a selective and potent oral Polθ inhibitor as a potent synergistic partner for PARPi, particularly in the context of BRCA1/2 mutations. SYX1097 exhibits remarkable helicase inhibitor potency, coupled with outstanding animal efficacy, pharmacokinetic characteristics and safety profiles. SYX1097 potentiates an extensive therapeutic window, as evidenced by its efficacious dose levels observed in pre-IND studies. IND enabling studies have been completed and GMP manufacturing is underway, further advancing SYX1097 towards clinical development.

https://www.abstractsonline.com/pp8/#!/20272/presentation/11668